Edition:
United States

Pain Therapeutics Inc (PTIE.O)

PTIE.O on Nasdaq

4.24USD
8 Dec 2017
Change (% chg)

$0.19 (+4.69%)
Prev Close
$4.05
Open
$4.09
Day's High
$4.43
Day's Low
$4.00
Volume
82,433
Avg. Vol
281,610
52-wk High
$9.31
52-wk Low
$3.10

Latest Key Developments (Source: Significant Developments)

Pain therapeutics reports Q3 loss per share $0.40
Wednesday, 1 Nov 2017 08:00am EDT 

Nov 1 (Reuters) - Pain Therapeutics Inc :Pain therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.40.Pain Therapeutics Inc - ‍still expects net cash usage in calendar year 2017 may be approximately $10 million​.Pain Therapeutics - ‍following resubmission of Remoxy NDA in Q1 2018, Co believes net cash usage in 2018 will decrease significantly compared to 2017.  Full Article

Pain Therapeutics announces upcoming meeting with FDA
Monday, 30 Oct 2017 08:00am EDT 

Oct 30 (Reuters) - Pain Therapeutics Inc :Pain Therapeutics announces upcoming meeting with FDA.Pain Therapeutics - ‍U.S. FDA agreed to pre-nda guidance meeting to discuss co's NDA resubmission for remoxy er as a treatment for severe chronic pain​.Pain Therapeutics Inc - ‍meeting is planned for November 14, 2017 at FDA headquarters​.Pain Therapeutics Inc - ‍remoxy NDA remains on-track for a planned resubmission in Q1 2018​.  Full Article

Pain Therapeutics announces positive regulatory guidance for Remoxy ER
Monday, 20 Mar 2017 08:57pm EDT 

Pain Therapeutics Inc : Pain Therapeutics announces positive regulatory guidance for Remoxy ER . Believe its now on track to make expeditious progress toward resubmission of Remoxy NDA . Pain Therapeutics Inc - expect to complete remoxy studies by year-end 2017, at a cost of approximately $3 mln-$4 mln .Agreement reached with FDA on additional studies that are needed for Remoxy's approval.  Full Article

Pain Therapeutics announces positive regulatory guidance for Remoxy ER
Monday, 20 Mar 2017 06:59pm EDT 

Pain Therapeutics Inc : Pain Therapeutics announces positive regulatory guidance for Remoxy ER . Believe its now on track to make expeditious progress toward resubmission of Remoxy NDA . Pain Therapeutics Inc - expect to complete remoxy studies by year-end 2017, at a cost of approximately $3 mln-$4 mln .Agreement reached with FDA on additional studies that are needed for Remoxy's approval.  Full Article

Pain Therapeutics Q2 loss per share $0.07
Tuesday, 19 Jul 2016 04:30pm EDT 

Pain Therapeutics Inc : Pain Therapeutics reports Q2 2016 financial results .Q2 loss per share $0.07.  Full Article

Durect says PDUFA date for remoxy NDA of Sept 25 unchanged
Friday, 1 Jul 2016 09:05am EDT 

Durect Corp : Says prescription drug user fee act (PDUFA) date for remoxy NDA of September 25, 2016 is unchanged . An FDA advisory committee meeting for remoxy is not needed and no change to September 25, 2016 PDUFA date . Pain Therapeutics stated that FDA advised them that regulatory review of remoxy new drug application (NDA) remains active and on-going .Durect provides remoxy update.  Full Article

BRIEF-Pain therapeutics reports Q3 loss per share $0.40

* Pain therapeutics reports third quarter 2017 financial results